




# *The Advanced Technology Program: Innovative Technology Solutions Through Industry-led Public Private Partnership*

Michael D. Amos, Ph.D. Project Manager  
Chemistry and Life Sciences Office,  
Advanced Technology Program  
National Institute of Standards & Technology  
Gaithersburg, Maryland

To accelerate the development of  
**innovative technologies** for  
**broad national benefit** through  
**partnerships** with the private sector.




# Sixteen Years of Innovation



Drug Discovery Technologies

DNA Diagnostics



DVD



HDTV



Fuel Cells



Biomanufacturing

Aquaculture

Homeland Security

Tissue Engineering

Discrete Manufacturing




# *ATP Historical Funding Mechanisms*

## Open or General Competitions

- Competitions since 1991


## Focused Programs

- Industry-led cooperative programs in several key technology areas
- Conducted in '94, '95, '97 & '98



# *ATP: Process At-A-Glance*


- Funding source of “last resort”
- Focus is on high-risk, high-payoff civilian technology development
- Well-established processes for proprietary handling of proposals
- Proven peer-review system
- Document control, Human & Animal subjects, Legal and Grants support
- Evaluation of multidisciplinary proposals
- Value-added project management



# *ATP Selection Criteria*

**50% - Scientific and Technological Merit**

**50% - Potential for Broad-Based  
Economic Benefits**






# *ATP Selection Criteria*

## Scientific and Technological Merit (50%)

- Technical Rationale
  - Technological innovation
  - High technical risk & feasibility
- R&D Plan


## Potential for Broad-Based Economic Benefits (50%)

- Economic Benefits
- Need for ATP funding
- Pathway to Economic Benefit




# Types of Proposals

## As a Single Company:



- For-profit company
- 3-year time limit
- \$2M award cap
- Company pays indirect costs
- Large companies cost share at least 60% of total project cost

## As a Joint Venture:



- At least 2 for-profit companies
- 5-year time limit
- No limit on award amount (other than availability of funds)
- Industry share >50% total cost

- *ATP encourages teaming arrangements*
- *Most projects involve alliances*



# *Last Review Process*

PROPOSALS

SCREENING

CLASSIFICATION

**Gate 1: FULL TECHNICAL PLAN + PRELIMINARY ECON/BUS PLAN**

<p><b>TECHNOLOGICAL MERIT</b></p> <ul style="list-style-type: none"> <li>• Technical Rationale             <ul style="list-style-type: none"> <li>– technological innovation</li> <li>– high technical risk &amp; feasibility</li> </ul> </li> <li>• R&amp;D Plan</li> </ul>	<p><b>ECONOMIC/BUSINESS MERIT</b></p> <ul style="list-style-type: none"> <li>• National Economic Benefits</li> <li>• Need for ATP Funding</li> <li>• Pathway to Economic Benefits</li> </ul>
--	--

**Gate 2:  
FULL ECONOMIC/BUSINESS  
PROPOSAL + BUDGET INFO**


**Gate 3: SEMIFINALISTS  
IDENTIFIED**

- Oral review

**Gate 4: AWARD**


**Cooperative  
Agreement**

**DEBRIEFING**



# Gate 1: Complete Technical Plan


- Fully address “scientific and technological merit” selection criterion
  - Technical Rationale
    - **technological innovation**
    - **high technical risk & feasibility**
  - R&D Plan
- Single company -- **20 pages max**
- Joint venture -- **30 pages max**



# *Understanding Technology Innovation*

## Innovation at ATP

- Unique approach to developing new-to-the-world prototypes of
  - Products
  - Processes
- Approach can be
  - Completely new
  - Novel integration of existing or new technologies







## Revolutionize the State-Of-The-Art

- Better
- Cheaper
- Faster
- “Disruptive”

## Revolutionary – Not Evolutionary

## Project Deliverables – Not Product Development

- Platform multi-use technologies
- Prototype new tools
- Prototype new processes
- Prototype new products


# High Technical Risk And Feasibility

## High Technical Risk

- technical challenges
- significant uncertainty of success
- risky innovation or integration

## Feasibility

- sound scientific foundation
- sound engineering approach



**ATP proposals balance both!**

*How will you achieve your goals?*




*Essential Elements of a Quality R&D Plan*



## *Gate 2: Complete Economic/Business Plan*


- Fully address “potential for broad-based economic benefits” selection criterion
  - **National Economic Benefits**
  - **Need for ATP Funding**
  - **Pathway to Economic Benefits**
- Single company -- **15 pages max**
- Joint venture -- **20 pages max**





***ATP Perspective***  
**ATP cares about  
net benefits for the nation**


***Private Investor Perspective***  
**Private investors care about near  
term return on their investment**



**What market opportunity will be missed without ATP funding?**

**Why does the project need public funds?**

- Is the project “too risky” to obtain private or internal funding?
- Where else have you looked for funding and why were you turned down?





What is your **strategy**, **plan**, and **project structure** for realizing national economic benefits?

**Commercial-  
ization  
Plan and  
Strategy**

**Spillovers and  
Broader  
Diffusion**


**Commitment  
Organizational  
Structure &  
Management**

**Experience  
and  
Qualifications**

**U.S.  
Economic  
Growth**


## *Gate 3: Semifinalist*

- **Semifinalist**, invited to NIST for an oral review, and may be asked to provide written responses to questions for clarification



## *Gate 4: Award*

- If selected, an award is made
- A cooperative agreement is issued by the NIST Grants Officer





# *ATP Adult Stem Cell Project Awards*

Cytomatrix, Inc. – 1999 - T Cell Production in an Artificial Thymus

Osiris Therapeutics, Inc

1997 -Cardiac Muscle Regeneration Using Mesenchymal Stem Cells

1998 -Bone Regeneration Using Allogenic Mesenchymal Stem Cells

2002 - Neural Regeneration with Mesenchymal Stem Cells

ACT Group, Inc. – 2003 - Transdifferentiation of Adult Somatic Cells

RheoGene, Inc. – 2004 - Novel Technologies for Adult Stem Cell Therapeutics

# *ATP Adult Stem Cell Project Awards*



Aastrom, Inc., 1992 - Human Stem Cell and Hematopoietic Expansion Systems

Progenitor, Inc - 1994 - Application of Gene Therapy to Treatment of Cardiovascular Diseases


Automated Cell, Inc – 1997 - Combinatorial Cell Culture: Tool Development and Application to Human Stem Cell Growth

Alexion Pharmaceutical Inc. – 1997 - Xenogeneic Cartilage Transplantation

Revivacor, Inc. – 2000 - Autologous Stem Cell Production

# *Project Management Basics*

- Project Management Team
  - Technical specialist
  - Business specialist
  - Grants specialist
- Technical Reports
  - Quarterly reports
  - Final technical report
- Annual Business Reports
- Financial Reports
- Formatted Business Reports
- Human & Animal Subjects
- Managing Change
  - Advance approval for >10% change of currently approved annual budget
  - Changes to approved tasks require criteria integrity






# *Project Management Values*


## Objectives

- Maintain fidelity to original proposal and cooperative agreement governing the award
- Continued fidelity of project to its original merit against ATP selection criteria
- Monitor progress through reports and other communications
- Monitor technological and business environments
- Company makes all business decisions




# *Project Management Pointers*

- Avoidable Issues
  - Not reading and knowing the rules
  - Bad assumptions – Human & Animal Subjects
  - Inaccurate accounting
  - Technical or Budget changes without prior approval
- Unavoidable Issues “let’s talk”
  - Key Personnel leave
  - Subcontractor issues
  - Bankruptcy
  - Company is sold
  - Company is sold and doesn’t want the grant
  - Company is sold to foreign entity



# *Sixteen Years of Innovation*


- Since 1990, 44 competitions
  - 6,924 proposals, \$14.7 billion requested from ATP
- 768 projects awarded
  - 1,511 participants and >1500 subcontractors
- \$4.4 billion of high-risk research funded
  - *ATP share > \$2.3 billion*
  - *Industry share > \$2.1 billion*
- Small businesses are thriving
  - *66% of projects led by small businesses*
- Over 1,100 patents from ATP projects






# 768 ATP Award Funding Breakdown

(As a Percent of \$2.3 B Awarded)



**34%**  
**Large Companies**



# *Stimulating U.S. Economic Development*

## ATP accelerates technology development

- 86% of project participants report that they are ahead in their R&D cycle as a result of ATP funding
- Over half said that they are ahead by 1 to 3 years

## ATP fosters collaboration


- 85% of projects engaged in collaborations with other companies, universities and federal labs

**ATP Published Studies - [http://www.atp.nist.gov/eao/eao\\_pubs.htm](http://www.atp.nist.gov/eao/eao_pubs.htm)**

# *Stimulating U.S. Economic Development*

## Considerable evidence ATP is achieving its objectives

- Increased rates of innovation
- Broadly enabling technology platforms
- Commercialization by U.S. companies
- Improved competitiveness of U.S. industries
- Broadly distributed economic benefits from large spillovers
- Increased collaborations
- Strong small business participation
- ATP a strong causal factor—leveraging, not substituting





## *For Info on ATP and to Join Our Mailing List . . .*

- Call toll-free: 1-800-ATP-FUND  
(1-800-287-3863)
- Fax your name and  
address to: 301-926-9524
- Send e-mail to: ***atp@nist.gov***
- Visit ATP's website: ***http://www.atp.nist.gov***

# Thank You

